AET - Investors Have Misdiagnosed Amazon's Push Into The Pharmacy Business
Companies everywhere, in every business, are paranoid about Amazon.com (AMZN). This sort of paranoia is healthy for the long-term well-being of our investment portfolio, as it is creating interesting buying opportunities.
A case in point: My firm spent a lot of time thinking about pharmacies when we were analyzing investments in McKesson (MCK) and other drug distributors. We struggled with a question: How will the retail pharmaceutical industry look in the future? Or more precisely, how will Amazon's entrance into the retail pharmacy business change this industry?
Our inability to answer this question kept us